Jonathan Paul
Cardiovascular Disease · Chicago, ILNPI 1134358146
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,825 of the $23,522 with a category attached, or 75.8%. 19 manufacturers reported payments, led by Angiodynamics, Inc. at 52.0% of the total. Reporting peaked in 2024 at $13,323 and has fallen 93.9% since, to $813 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $188.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$12K
- Boston Scientific$6K
- Inari Medical, Inc.$3K
- Abiomed$852
- Argon Medical Devices, Inc.$622
- Abbott$402
- plus $990 from 13 others
Across 22 payments — averaging $3914.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$72K
- AstraZeneca$6K
- Argon Medical Devices, Inc.$5K
- Penumbra, Inc.$2K
- Astrazeneca UK Limited$1K
What the payments were for
- Consulting fees$17,82576%
- Speaking & faculty fees$1251%
- Travel & lodging$6503%
- Food & beverage$4,82220%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 4 | $12,240 |
| Boston Scientific | 14 | $5,549 |
| Inari Medical, Inc. | 43 | $2,866 |
| Abiomed | 19 | $852 |
| Argon Medical Devices, Inc. | 3 | $622 |
| Abbott | 15 | $402 |
| Medtronic | 4 | $229 |
| Kerecis Limited | 1 | $222 |
| AstraZeneca | 2 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $89 |
| Cardiva Medical, Inc. | 5 | $73 |
| Acist Medical Systems, Inc. | 3 | $59 |
| Stryker | 2 | $44 |
| Cardiovascular Systems Inc. | 1 | $36 |
| Pfizer | 1 | $33 |
| Terumo Medical Corporation | 1 | $27 |
| Edwards Lifesciences | 1 | $23 |
| Teleflex LLC | 1 | $21 |
| ZOLL Circulation Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AlphaVac$12,000
- GENERAL VASCULAR INTERVENTION$3,008
- CT THROMBECTOMY SYSTEM KIT$2,414
- EKOSONIC$2,025
- Kerecis Omega3 SurgiClose$667
- CLEANER$419
- FLOWTRIEVER CATHETER, S$414
- GENERAL - THERAPIES$350
- FlowTriever$313
- ClotTriever$313
- GENERAL PAIN MANAGEMENT$262
- Impella$233
- Kerecis Omega3 GraftGuide$222
- Kerecis Omega3 Marigen$222
- AngioVac$179
- SYMPLICITY G3$163
- THROMBECTOMY$125
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$116
- GENERAL - STENTS$113
- ANGIOJET$100
How this compares
$23,522 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 23 | $35,996 |
| JardianceEmpagliflozin | 21 | $25,218 |
| EliquisApixaban | 11 | $15,566 |
| Repatha SureclickEvolocumab | 12 | $11,139 |
| FarxigaDapagliflozin Propanediol | 14 | $9,107 |
| VascepaIcosapent Ethyl | 14 | $5,575 |
| Atorvastatin Calcium | 33 | $647 |
| Metoprolol Succinate | 38 | $423 |
| Rosuvastatin Calcium | 23 | $333 |
| Carvedilol | 19 | $214 |
| Amlodipine Besylate | 20 | $207 |
| Losartan Potassium | 17 | $176 |
| Spironolactone | 21 | $90 |
| Lisinopril | 21 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $15,56611 claims |
| AstraZenecaFarxiga | $116 | $9,10714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Chicago
- Sandeep NathanChicago$892K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Michael DavidsonChicago$317K
- Jyothy PuthumanaChicago$269K
- Sanjiv ShahChicago$246K
- Raja MutharasanChicago$146K
- Nitasha SarswatChicago$140K
- Evan SteinChicago$121K
- Dan FintelChicago$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.